Johannes MD - Roche Holding Head Devel
RHHVF Stock | USD 286.70 2.34 0.81% |
Insider
Johannes MD is Head Devel of Roche Holding AG
Age | 66 |
Phone | 41 61 688 11 11 |
Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Nadim Ahmed | Bristol Myers Squibb | 51 | |
Pascale Schmidt | Roche Holding AG | 50 | |
Paul Penepent | Novartis AG ADR | N/A | |
Karen Hale | Novartis AG | 55 | |
Minoru Kikuoka | Astellas Pharma | N/A | |
Suketu Desai | Scilex Holding | 58 | |
Barbara Schadler | Roche Holding Ltd | 61 | |
Michael Preuss | Bayer AG | N/A | |
Bruno Eschli | Roche Holding AG | N/A | |
Barbara Schadler | Roche Holding AG | 61 | |
Gonzalo Vina | AstraZeneca PLC | N/A | |
Greg Meyers | Bristol Myers Squibb | 51 | |
Bruno Mnard | Sanofi ADR | N/A | |
Nuria Lapea | Grifols SA ADR | 60 | |
Claudia Bockstiegel | Roche Holding AG | 59 | |
Timothy Power | Bristol Myers Squibb | N/A | |
Robert PharmD | Novartis AG ADR | 56 | |
Victor Bulto | Novartis AG ADR | 46 | |
Collette Taylor | Astellas Pharma | 60 | |
Montserrat Llamas | Grifols SA ADR | 59 | |
Tim Power | Bristol Myers Squibb | N/A |
Management Performance
Return On Equity | 0.45 | |||
Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications | ||
Claudia Bockstiegel, G Counsel | ||
Bruno Eschli, Head Relations | ||
Johannes MD, Head Devel | ||
Thomas Schinecker, Chief Diagnostics | ||
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
Alan Hippe, CFO and IT Officer | ||
Severin Schwan, CEO and Director | ||
Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.45 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.32 % | |||
Current Valuation | 287.91 B | |||
Shares Outstanding | 693.89 M | |||
Shares Owned By Institutions | 40.30 % | |||
Price To Earning | 18.04 X | |||
Price To Book | 9.57 X | |||
Price To Sales | 3.97 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Roche OTC Stock
Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.